Sativex in MS spasticity - real life data
Survey confirms practical use and benefits of Sativex (1)
In a published patient survey, investigators asked MS patients to describe how their use of healthcare resources and specific functioning activities had changed since starting on Sativex.
- Median duration of MS was 17.0 years (range: 3-40 years) in these patients (implying that they were likely to represent a group with a significant level of disability)
- Median duration of Sativex use was 27 months (range: 1-120 months)
Results indicate MS patients show long-term improvements in many aspects of daily living (1)
MS patients were asked to report how their specific functional abilities had changed since starting on Sativex.
Results indicate reduction in MS patients' use of healthcare resources (1)
Results indicate reduction in the burden of care for caregivers is a common experience (1)
66 of the MS responders had caregivers, the majority described themselves as a partner. When asked whether there had been an overall benefit from treatment with Sativex:
- 82% said they benefited
- William G. Notcutt. A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine. Primary Health Care Research & Development, Available on CJO 2012 doi:10.1017/S1463423612000333.